Cargando…
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
Direct in vivo administration of messenger RNA (mRNA) delivered in both naked and nanoparticle formats are actively investigated because the use of dendritic cells transfected ex vivo with mRNA for cancer therapy is expensive and needs significant infrastructure. Notably, intravenous and subcutaneou...
Autores principales: | Phua, Kyle K. L., Staats, Herman F., Leong, Kam W., Nair, Smita K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044635/ https://www.ncbi.nlm.nih.gov/pubmed/24894817 http://dx.doi.org/10.1038/srep05128 |
Ejemplares similares
-
Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines
por: Phua, Kyle K. L.
Publicado: (2015) -
Cytokines: The Future of Intranasal Vaccine Adjuvants
por: Thompson, Afton L., et al.
Publicado: (2011) -
Suppression of mRNA Nanoparticle Transfection in Human Fibroblasts by Selected Interferon Inhibiting Small Molecule Compounds
por: Liu, Yang, et al.
Publicado: (2017) -
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
por: Lutz, Johannes, et al.
Publicado: (2017) -
mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022)